Exiqon to Shut Down California Lab After Reimbursement Issue Stymies Sale Talks | GenomeWeb

By Doug Macron

Exiqon last week announced that it intends to shut down Oncotech, its Tustin, Calif.-based clinical laboratory improvement amendments-certified lab, after reimbursement problems stymied the company's efforts to sell the unit.

Despite the setback, the Danish company remains on track with its strategy of marketing its microRNA-based diagnostics in collaboration with partners, and expects to announce a deal before the end of the year, a company official said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.